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Abstract
Background: Numerous gene lists or "classifiers" have been derived from global gene expression
data that assign breast cancers to good and poor prognosis groups. A remarkable feature of these
molecular signatures is that they have few genes in common, prompting speculation that they may
use distinct genes to measure the same pathophysiological process(es), such as proliferation.
However, this supposition has not been rigorously tested. If gene-based classifiers function by
measuring a minimal number of cellular processes, we hypothesized that the informative genes for
these processes could be identified and the data sets could be adjusted for the predictive
contributions of those genes. Such adjustment would then attenuate the predictive function of any
signature measuring that same process.
Results: We tested this hypothesis directly using a novel iterative-subtractive approach. We
evaluated five gene expression data sets that sample a broad range of breast cancer subtypes. In all
data sets, the dominant cluster capable of predicting metastasis was heavily populated by genes that
fluctuate in concert with the cell cycle. When six well-characterized classifiers were examined, all
contained a higher than expected proportion of genes that correlate with this cluster.
Furthermore, when the data sets were globally adjusted for the cell cycle cluster, each classifier lost
its ability to assign tumors to appropriate high and low risk groups. In contrast, adjusting for other
predictive gene clusters did not impact their performance.
Conclusion: These data indicate that the discriminative ability of breast cancer classifiers is
dependent upon genes that correlate with cell cycle progression.
Background
Global gene expression profiling of breast tumors has pro-
vided considerable insight into the biological processes
underlying this disease [1-3]. One application of gene
expression data has been the development of prognostic
"molecular signatures" or classifiers – short lists of genes
that can be used to assign tumors to good or poor prog-
nostic groups [4-11]. Some classifiers have now become
commercially available diagnostic tools for breast cancer,
making it imperative to understand how they function as
well as how they differ from one another. A notable fea-
ture of published prognostic gene lists is that they have
relatively little overlap in terms of composition. This lack
of commonality has led to the proposition that prognostic
lists use different genes to measure the same underlying
biological process(es) [12,13]. Evidence supporting this
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notion includes a study evaluating the predictive abilities
of five prognostic gene lists using a common gene expres-
sion data set, which showed that four of the five classifiers
examined performed comparably in predicting future
metastases despite having almost no overlap in constitu-
ent genes [14]. Where there is overlap between gene lists,
the established function of many of the common genes is
regulation of cell cycle progression [7]. Thus, gene expres-
sion signatures predictive of tumor grade, which are
highly enriched in cell cycle genes, tend to have the great-
est overlap with other gene lists [15,16]. It has further
been demonstrated that, for some lists, the performance
of the full list can be recapitulated using only the cell
cycle-related genes contained within that list [15,17]. This
indicates that cell cycle genes are sufficient to create an
effective classifier [18]. In contrast to the sufficiency of
known cell cycle regulators to predict outcome, the extent
to which established classifiers actually depend upon cell
cycle-correlated genes has not been determined.
Gene expression data contains numerous clusters, or
groups, of genes whose patterns of expression are highly
correlated across tumors [19,20]. As a result, the expres-
sion of many different genes can be used as surrogate
measures for a common pathological process. Thus, prog-
nostic gene lists need only to select a single gene from a
highly correlated gene cluster to capture the overall
expression pattern of all genes within that cluster. If each
prognostic gene list utilized a different gene from a corre-
lated set, the lists would have no overlap in gene identity,
but would perform comparably because they would effec-
tively measure the same cellular activity. We sought to
determine whether this phenomenon was occurring with
prognostic gene lists for breast cancer metastases. Herein,
we describe the identification of clusters of correlated
genes that are associated with the risk of developing
metastases. We then determined the extent to which pub-
lished classifiers utilized these gene clusters to predict out-
come. Using five independent data sets, we show that all
published prognostic gene lists that we examined rely
upon a single group of correlated genes to predict out-
come. Notably, the most predictive members of this clus-
ter were genes which showed a cell-cycle pattern of
regulation.
Methods
Previously published microarray datasets
Three publicly available breast cancer gene expression
data sets were analyzed in the primary analyses: the Neth-
erlands Clinical Institute (NKI2) data, which contains
clinical (including metastatic recurrence latencies) and
gene expression data on 295 women [9,21]; the Wang
data set containing gene expression data on 296 women
with lymph node negative disease [10] (GEO series
GSE2034); and the KJX64 and KJ125 data sets containing
data on 189 women, 64 of which were treated with
tamoxifen, with primary operable invasive breast cancer
[15] (GEO series GSE2990).
Gene expression data for the NKI2 data set were deposited
as log10 expression ratios. For analyses identifying predic-
tive clusters of correlated genes, a data set that contained
no duplicated genes was created. Each probe in the data
set was mapped to a gene symbol using the SOURCE data-
base (source.stanford.edu). Gene symbols were identified
for 21,220 probes. All probes that had complete data on
more than 291 of the 295 subjects were used in the anal-
ysis. Missing values were imputed using the "impute"
option from FastClus procedure (SAS). For genes for
which there were multiple probes in the data set, the
median expression value was used. The final data set con-
tained complete data for 14,870 uniquely named genes.
For all other analyses, all probes in the complete NKI2
data set were used.
For the Wang, KJX64 and KJ125 data sets, all probes (n =
22,286 in Wang and n = 22,285 in KJX64/KJ125) in each
data set were used in all analyses. In the Wang data set,
expression values were log2 transformed. Expression data
from the KJX64 and KJ125 data sets was provided as log2
values. During data analyses, we noted that there were
unexpectedly high rates of positive correlations among
probes in the KJX64 and KJ125 data sets. To attenuate
these correlations, expression data for each probe was nor-
malized by dividing the values for each probe by the
median expression value of all probes for a given subject.
Simulated gene expression data set
As proof of concept of our iterative-subtractive approach
for identifying the determinant groups of genes that dic-
tate prognostication in a gene expression dataset, we
began with a simulated gene expression data set. This data
set was comprised of 300 subjects and contained 3 sets of
correlated genes, two of which were associated with out-
come, and was generated as follows. First, simulated
expression data for 1000 uncorrelated genes was gener-
ated for each subject using a random number generator
derived from a normal distribution (mean = 0, variance =
2). Next, we generated clusters of correlated genes: a "par-
ent" gene was randomly selected from the 1000 genes and
the expression of additional genes were then computed to
have expression values equaling the "parent" gene's
expression value plus a random number drawn from a
normal distribution of values having a mean of 0 and var-
iances ranging from 1 to 7. The degree of correlation was
determined by the magnitude of the variance. Three "par-
ent" genes were selected to generate correlated clusters of
either 120 (parent genes 1 and 2) or 240 (parent gene 3)
genes. The larger cluster was generated to demonstrate
that the size of the cluster does not impact the analysis.BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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Finally, event and latency data were randomly assigned
based on expression quartiles of gene1 and gene2, with
increased expression of these genes being associated with
an increased risk of an event. For each of these genes, the
respective risk of an "event" across quartiles was randomly
determined with probabilities of 0%, 5%, 20% and 30%
and the latencies in the instance of an event were ran-
domly generated to have mean values of 5, 4, 3 and 2
years. After generating the simulated data, the univariate
Cox proportional hazard ratios for gene1, gene2 and
gene3 were 1.4 (p < 0.0001), 1.2 (p = 0.0007) and 0.9 (p
= 0.06), respectively.
Published gene lists
The published prognostic gene lists analyzed here were
selected because they all effectively stratify patients into
high and low risk prognostic groups using data sets com-
prised of both estrogen receptor (ER) negative and ER pos-
itive tumors. Using these classifiers, we assigned tumors to
high and low risk groups following the authors' published
methods, except where otherwise noted. When assign-
ment of tumors to high and low risk groups involved the
use of training sets, subjects used in the training sets were
not included in the subsequent analyses evaluating the
performance of the predictor. For each data set, these
training sets were comprised of a random set of subjects,
except for the NKI2 data set, where the training set for
"good" prognosis subjects (subjects who did not experi-
ence metastases within 5 years) were the 30 subjects who
did not experience metastases and where the conservFlag
variable was either +1 or -1 [9]. The numbers of subjects
used in training sets varied, hence the statistical analyses
for the selected gene lists may involve different numbers
of subjects and the relative performance of a list with
respect to other lists may not be directly comparable.
Gene symbols, accession numbers or probe identifiers
from prognostic lists were extracted from materials
accompanying the original publications and mapped to
probe identifiers in each expression data set using Uni-
gene cluster IDs derived from the SOURCE database.
Unless otherwise noted, each instance of a matching
probe was used in the analyses. For some prognostic gene
lists, there were genes that could not be mapped to a
probe in a given expression data set. A list of the number
of probes used to compute prognostic scores and the
numbers of subjects used in training sets is summarized
[see Additional file 2].
The "70-gene" prognostic score was computed as
described previously [9,11]. A 90% sensitivity (10% false
positive) threshold was used to assign tumors to high and
low risk groups. The "76-gene" predictor was computed as
described by the authors, with one exception: a 90% sen-
sitivity threshold was used to establish cut-off values for
high and low risk tumors in the training sets rather than a
100% threshold since some tumors had outlying values in
some data sets and this slightly lower threshold enhanced
the performance of the classifier [10]. Weighted hazard
ratio coefficients for all analyses were computed using
unadjusted data. Because the "76-gene" predictor uses
separate gene lists for ER positive and negative tumors,
each list of genes was analyzed separately. The "Wound
Signature" prognosticator was only examined in the NKI2
data sets since computations for this prognosticator relied
upon centroid values previously computed by the authors
[4]. The centroid values for "activated" (poor prognosis)
tumors were obtained from the author's supplemental
data files [4]. A 90% sensitivity classifier was used to
define high and low risk groups. The "Histological grade
signature" was computed as described by the authors,
with the exception that a 90% sensitivity threshold was
used for group assignment [15]. The probe identifiers for
each of the data sets analyzed were previously mapped by
the authors and were available as a supplement to the
original publications. The Naderi prognostic score was
computed as described by the authors, except that all
probes mapped to each data set were individually used in
the computations [6]. Finally, the 21 gene "Recurrence
Score" was analyzed only in ER positive tumors. The score
was computed as described by the authors [8]. In gene
expression data sets where there were multiple probes for
a given gene, the median value of the probes was used.
Expression data for each gene analyzed was adjusted to
have a mean value of 7.5 to ensure that expression values
fell within the ranges reported by the authors. Since data
adjustment precluded the use of fixed cut-off points to
define high and low risk groups, as described by the
authors, the performance of the predictor was analyzed by
either ROC analysis or a 90% sensitivity classifier. Expres-
sion data from the NKI2 data were transformed to log2
values when computing the Recurrence score.
Survival analyses
All survival analyses are based on 5-year metastatic recur-
rence latencies. All subjects not experiencing metastases
within 5 years were censored at that time point. Cox pro-
portional hazards regression models were used to meas-
ure the strength of the association between the covariates
and recurrence (PHReg procedure). For most analyses,
univariate proportional hazards ratios comparing good
and poor prognostic groups are reported. For multivaria-
ble models, the most parsimonious set of covariates was
determined using forward and backward selection meth-
ods on all clinical covariates contained within each data-
set. In the NKI2 data set, these were determined to be age
(in years), tumor size, ER status (ER positive vs. ER nega-
tive) and grade (1 vs. 2 and 1 vs. 3). In the KJX64/KJ125
data set, the covariates were tumor size (> 2 cm vs. < 2 cm)
and grade (grade 2 vs. grade 1/3). ER status was the only
clinical covariate contained in the Wang data set. Princi-BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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pal component variables were standardized to have a
mean of 0 and standard deviation of 1 in proportional
hazards models.
Identifying predictive clusters of correlated genes
The following approach was taken to iteratively identify
clusters of positively correlated genes associated with the
risk of developing metastases in each data set. This
method assigns a rank to each gene probe within a data set
such that a highly ranked probe has the following proper-
ties: 1) it is strongly predictive of outcome (i.e. it has a low
univariate hazard ratio (HR) p-value); 2) its expression is
highly positively correlated with other probes; and 3) the
HR p-values of the positively correlated probes decreases
in direct proportion to their correlation with the gene
being ranked. The rationale for the third criteria is that
many probes may be associated with outcome solely
because their expression pattern follows, to various
degrees, the expression pattern for a highly predictive
gene.
First, a univariate Cox proportional hazards p-value was
computed for each probe to identify probes predictive of
metastatic tumor latencies (PHReg procedure). Only
probes with a HR p-value less than 0.05 were further ana-
lyzed in the breast cancer gene expression data sets. For
the simulated data set, all probes with p-values less than
0.5 were analyzed. Next, for each probe, its linear Pear-
son's correlation coefficient (r) to every other probe was
calculated. A new Pearson's correlation coefficient (corr)
and covariance (cov) value was then computed for each
probe using the correlation coefficients (r) and the
log10(HR p-values); these new correlation and covariance
values were computed using only those genes that were
positively correlated with the probe being examined. Each
probe was then assigned a score based on the following
computation:
Score = AbsoluteValue(Cov (r, log10(HR p-value))) * 
Corr(r, log10(HR p-value)).
A graphical representation of two potential outcomes of
the scoring procedure is provided [see Additional file 1].
The covariance component of this score gives increased
weight to probes that are positively correlated with a large
number of genes that are highly predictive of survival (i.e.
have small p-values). The Pearson's correlation compo-
nent of this score gives increased weight to those probes
for which there is a linear relationship between its corre-
lations with all other probes and their HR p-values. In
total, this score ranks each probe in the data set such that
those with the lowest (i.e. most negative) values are the
most predictive members of clusters of correlated genes
associated with the risk of developing metastases.
After assigning scores to each probe, the top 10 ranked
genes (the genes with the lowest scores) were selected as
representatives of the cluster. If the expression levels for
these genes was highly correlated across tumors, this
would indicate that a cluster of correlated genes associated
with metastases had been identified. Having identified a
cluster, the "average" expression pattern of the 10 genes
was measured by computing the first principal compo-
nent (PC) for the 10 genes (Princomp procedure). The PC
represents a new variable that is maximally correlated
with the expression values of the top 10 genes. We then
used the PC variable to globally adjust the data set thereby
eliminating correlations between the top 10 genes and all
other genes (described below). After this global adjust-
ment, the next predictive cluster of genes could be identi-
fied by repeating this entire scoring process using the
adjusted data.
Global adjustment of gene expression data
Identification of subsidiary principal components
required the selective elimination of correlations between
probes and a previously identified PC variable. To accom-
plish this, the expression data were globally adjusted for
either an individual gene probe or a principal component
(PC) variable by fitting a least-squares regression line
(which included an intercept term) to each probe in the
dataset and then computing the residuals (GLM proce-
dure). Each probe was the dependent variable and the
probe or the PC being adjusted for was the continuous
independent variable. The residuals (adjusted values) for
each probe represent the new expression values for that
probe. This adjustment removes the variance from each
probe that is linearly explained by the independent varia-
ble. The consequence of adjustment is that the adjusted
value (residual) for a probe is no longer linearly correlated
with the independent variable. Thus, probes that are pre-
dictive of metastases solely because their expression levels
are correlated with the independent variable will no
longer be predictive after adjustment. As a control for the
effects of globally adjusting data, expression values were
adjusted using a regression model that contained an inter-
cept term only, but no other covariates.
Statistical analyses
All calculations were performed using SAS version 9.1
(SAS Institute, Cary, NC). All statistical tests were two-
sided. All correlation values represent Pearson's correla-
tion coefficients. Receive operator characteristic (ROC)
curves were generated using the Logistic procedure and
were based on 5 year metastatic recurrence rates.
In the NKI2 data, expression values for probes typically
fell between the ranges of -1 and +1. In some instances,
the values for some probes represented extreme outliers.BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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Thus, observations for probes with absolute values greater
than 1.9 were omitted from these analyses.
Results
Development of a method for iteratively identifying 
clusters of correlated genes associated with an outcome
The multiple prognostic gene lists for breast cancer that
have been described have little overlap in their gene com-
position. We developed a method to sequentially identify
clusters of correlated genes that control the prognostic
power of these gene lists with the goal of identifying the
common underlying biological features of these classifi-
ers. Specifically, we devised an approach to identify clus-
ters of genes that are independently predictive of
metastases.
As a proof of principle of this method, we simulated a
gene expression data set that included 3 independent
groups, or clusters, of correlated genes. In two of the three
groups, we stipulated that one gene (named gene1 and
gene2) was correlated with an outcome. In the third
group, no genes were correlated with outcome. Using an
algorithm designed to identify genes belonging to predic-
tive clusters, we found that the top 10 ranked genes iden-
tified by this approach were gene1 and nine additional
genes that were highly correlated with gene1. Using a
principal component (PC) variable to represent the aver-
age expression of the top 5 ranked genes, a "cluster" of
positively and negatively correlated genes predictive of
outcome is easily visualized when plotting the p-value of
each gene's hazard ratio (HR) against its correlation to this
PC (Figure 1A). This cluster forms the boundaries of the
"V-shaped" pattern seen on the graph. This pattern arises
because the strength of an individual gene's relationship
to the outcome is dictated by the extent to which its
expression correlates with that of the PC. Genes with sig-
nificant p-values that are not correlated to the PC repre-
sent additional genes that are predictive of outcome but
are independent of this first gene cluster; these genes form
the top of the cone in the center of the graph.
We then used the PC variable to globally adjust the gene
expression data. This permitted repetition of the scoring
process, leading to identification of a second correlated
gene group that is independently predictive of outcome.
In the next iteration, the top 10 ranked genes were gene2
and genes highly correlated with it. This cluster is shown
in Figure 1B. Note that the overall magnitude of the p-val-
ues is smaller for this cluster since gene2 was less strongly
associated with outcome than gene1. On the next itera-
tion, a third correlated cluster of genes was identified that
was not strongly associated with outcome (Figure 1C). In
sum, these analyses demonstrate that clusters of corre-
lated genes independently predictive of outcome can be
sequentially identified, and that the order in which clus-
Identification of predictive, correlated gene clusters in a sim- ulated data set Figure 1
Identification of predictive, correlated gene clusters in a simu-
lated data set. A simulated expression data set that included 3 independ-
ent correlated gene clusters, two of which contained a gene associated 
with outcome (gene1 and gene2), as well as an additional set of uncorre-
lated probes was generated as described in the Methods. Each figure 
shows data for 901 simulated genes with a univariate hazard ratio (HR) p-
value less than 0.5. Each graph is a scatter plot of the negative log of the p-
value of the univariate HR for a gene versus its correlation to a principal 
component (PC) variable. The PC variable was derived from the expres-
sion values of the top 5 ranked genes representing the most predictive 
correlated gene cluster identified in the current iteration. A large value on 
the y-axis corresponds to a small p-value, indicating that a gene is strongly 
associated with outcome. A. The first correlated set of predictive genes 
identified on an analysis of unadjusted expression data. B. The second set 
of correlated genes identified after the expression data were adjusted for 
the first PC identified in graph (A). HR p-values were computed using the 
adjusted data. C. A third set of correlated genes was revealed after the 
data were sequentially adjusted for the PC variables identified in (A) and 
(B). Note that no additional correlated clusters of genes were identified 
that had small p-values, indicating that the 2 PC variables represented the 
two major clusters of genes predictive of outcome in the simulated data 
set, thereby confirming the efficacy of this approach.BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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ters are elucidated reflects the strength of their association
with the outcome.
Identification of correlated gene clusters associated with 
breast cancer metastases
To determine the basis for a lack of commonality between
breast cancer prognostic gene lists, we used the iterative-
subtractive method described above to identify gene clus-
ters associated with breast cancer metastases. We first eval-
uated the NKI2 data set, which is comprised of 295
women with early stage breast cancer [9]. In this data set,
3,311 genes had a univariate HR p-value for metastatic
recurrence of less than 0.05. These genes were then used
to identify groups of correlated genes that were predictive
of metastatic progression. In the first iteration, the major-
ity of the top-ranked genes in the first cluster were
involved in cell-cycle regulation and function [see Addi-
tional file 2]. A graph of the correlations between all genes
and a PC variable computed from the top 10 ranked genes
in this cluster is shown in Figure 2A. A striking feature of
this graph is that the vast majority of genes predictive of
metastases are correlated with the cell-cycle PC. Only 380
of the 3,311 genes analyzed remained significantly associ-
ated with metastases (p < 0.05) after the expression data
for each gene was adjusted for the PC. On the second iter-
ation, the top-ranked genes were predominantly involved
in protein translation [see Additional file 2]. Of note, only
a few genes were strongly correlated with this PC, and
their HR p-values were much lower than the genes highly
correlated with the first PC (Figure 2A). Repeated itera-
tions through this data set failed to identify any additional
large clusters of correlated genes that were strongly associ-
ated with the risk of developing metastases [see Addi-
tional file 2].
This approach was repeated with the KJX64/KJ125 data
sets, which are comprised of data from 189 women with
primary operable invasive breast cancer [15]. Similar to
the NKI2 data set, the top ranked predictive cluster of
probes was dominated by cell cycle genes (Figure 2B) [see
Additional file 2]. Of 1,282 probes initially analyzed, 255
retained significant HR p-values (p < 0.05) after adjusting
for this PC. The top ranked probes in the second cluster
were predominantly related to immune function (Figure
2B) [see Additional file 2]. Only 58 genes were still asso-
ciated with outcome after adjusting the data for this sec-
ond gene cluster. Additional predictive gene clusters were
not found among these remaining genes.
Using a third, independent data set, we found that the pri-
mary cluster in the Wang data set of 296 women with
lymph node negative disease [10] was also dominated by
a set of cell cycle related genes (Figure 2C) [see Additional
file 2]. Of the 4,088 probes initially analyzed, 1,490
remained predictive after adjusting for this cluster. The
next cluster consisted of relatively few correlated genes
predictive of outcome (Figure 2C) [see Additional file 2],
and was comprised of genes potentially related to TGF-β
or activin signaling [22]. This cluster was relatively small,
and 850 genes were still predictive after adjustment. The
top ranked genes in the third iteration were not consist-
ently correlated with each other and, thus, did not define
a correlated gene cluster [see Additional file 2].
In summary, the dominant predictive network in all three
independent expression data sets was a cluster of corre-
lated genes whose most predictive members were cell
cycle-associated. Similar results were obtained when anal-
yses were performed on two additional independent data
sets [see Additional file 2], i.e. the primary PC was domi-
nated by cell cycle correlated genes.
Each principal component variable is independently 
predictive of metastases in multivariable analyses
Multivariable Cox proportional hazards regression analy-
sis was performed to determine the relationship between
each principal component (PC) variable generated in the
previous analysis and the risk of metastasis. In each data
set, the first PC variable (representing the cell cycle gene
cluster) was significantly associated with metastases in all
tumors as well as in the subset of ER positive tumors, but
not the subset of ER negative tumors (Table 1). In the
NKI2 and Wang data sets, additional PC variables, such as
the one representing the TGF-β-like cluster (PC2 from the
Wang data set), were also significantly predictive of recur-
rence latencies in ER negative tumors. Hence, each of the
primary PC variables identified with the iterative-subtrac-
tive approach was independently predictive of the risk of
metastases in all breast tumors as well as in ER positive
tumors. This suggested that each of these could poten-
tially be used to generate novel classifiers. We tested this
supposition with each of the five data sets. In each case,
the cell-cycle PC variable performed comparably or better
than, the other previously characterized predictive lists
that we examined [see Additional file 2]. However, it
should be noted that the use of the same data sets to eval-
uate the PC classifiers may introduce intrinsic bias that
could enhance their performance.
Genes correlated with the cell cycle principal component 
are overrepresented on published prognostic gene lists
In all five data sets examined, the primary PC identified
consisted of a large set of cell cycle-associated genes, sug-
gesting that this gene cluster may significantly contribute
to the predictive ability of various prognostic lists that
were devised using such data. We determined the extent to
which previously reported prognostic lists included genes
from the correlated clusters by determining the percentage
of genes on each list that were moderately to strongly cor-
related with the first two PC variables from each data set. BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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Scatter plots showing the two most predictive clusters of correlated probes in three independent breast cancer gene expres- sion data sets Figure 2
Scatter plots showing the two most predictive clusters of correlated probes in three independent breast can-
cer gene expression data sets. Each graph is a scatter plot of the negative log of the p-value for a univariate HR versus the 
correlation of each probe to the first PC variable derived from the expression values of the top 10 ranked probes. For each 
data set, only probes which had a univariate HR p-value of less than 0.05 for 5 year metastatic recurrence latencies were exam-
ined. A. Scatter plots for the 3,311 probes in the NKI2 dataset based on (left panel) unadjusted and (right panel) data adjusted 
for the first PC variable. B. Scatter plots for the 1,282 probes in the combined KJX64 and KJ125 datasets based on unadjusted 
(left panel) and data adjusted (right panel) for the first PC variable. C. Scatter plots for the 4,088 probes in the Wang dataset 
based on unadjusted (left panel) and data adjusted (right panel) for the first PC variable.BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
Page 8 of 14
(page number not for citation purposes)
Each prognostic gene list contained a higher than
expected proportion of genes correlated with the cell cycle
PC (Figure 3). For example, using the NKI2 expression
data set, we found that only 1,200 of the 24,495 probes
(i.e. 4.9%) had an absolute correlation with this PC
greater than 0.4. In contrast, each of the previously
reported classifiers we examined contained between 18%
and 80% of probes with correlations of this magnitude.
The one exception was the Wang predictor for ER negative
tumors [10], which had no probes correlated with the cell
cycle PC. The predictive list with the highest proportion of
correlated probes was the grade signature, which was
developed using ER positive tumors [15]. Likewise, when
we examined other predictive gene lists derived from ER
positive tumors, we found a similar over- representation
of correlated genes. For example, in the proliferation sig-
nature [23], 100% of 50 probes were correlated to the cell
cycle PC, while the consensus signature [7] had 59% of 66
probes with similar correlations when evaluated in the
NKI2 data set (data not shown).
Few, if any, probes in the expression data sets were corre-
lated with the secondary PC variables. The notable excep-
tion was the Naderi prognostic gene list [6] in the KJX64/
KJ125 data set. Almost 10% (2–3 fold higher than
expected) of probes within this predictor had absolute
correlations greater than 0.4. In sum, these data show that
most prognostic gene lists are comprised of a higher than
expected number of genes whose expression is correlated
with the primary PC variable which measures fluctuations
in the cell cycle.
Prognostic gene lists depend upon the cell cycle principal 
component to identify good and poor prognosis tumors
To determine the extent to which the published gene-
based classifiers are dependent upon genes that are corre-
lated with the PC variables, we assessed the impact of glo-
bally adjusting the data using each PC variable on the
discriminating ability of the predictive lists. Most of the
gene lists were able to classify tumors into good and poor
prognosis groups with significant differences in recur-
rence latencies when data were globally adjusted using a
simple linear regression model that included only an
intercept term (Table 2). This indicated that the process of
global adjustment itself did not negate the predictive abil-
ities of the lists. In contrast, all but one of the gene lists
lost their ability to appropriately stratify tumors into sig-
nificantly different high and low risk groups following
Table 1: Multivariable Cox proportional hazards analysis for each principal component variable1.
All tumors ER positive tumors ER negative tumors
Data set Variable Hazard Ratio p-value Hazard Ratio p-value Hazard Ratio p-value
NKI2
PC1 1.8 0.0001 2.8 < 0.0001 0.9 0.61
PC2 0.6 < 0.0001 0.7 0.004 0.7 0.03
PC3 1.2 0.01 2.1 0.0002 1.1 0.37
Age 0.9 0.0009 0.9 0.01 0.9 0.02
Tumor size2 1.8 0.01 2.2 0.009 2.4 0.04
Grade 23 2.0 0.13 1.1 0.87
Grade 33 2.2 0.09 1.3 0.55
ER+ 0.9 0.67
KJX64/KJ125
PC1 1.5 0.004 2.2 < 0.0001 0.9 0.74
PC2 0.6 0.002 0.6 0.002 0.5 0.12
Grade 24 2.7 0.002 3.0 0.005 1.5 0.54
Tumor size2 3.2 0.002 4.4 0.002 1.8 0.42
Wang
PC1 1.8 < 0.0001 1.8 < 0.0001 1.7 0.06
PC2 1.6 < 0.0001 1.7 0.0003 1.6 0.02
PC3 2.0 < 0.0001 2.2 < 0.0001 1.5 0.05
ER+ 0.8 0.26
1. Up to three principal component variables (PC1-PC3), each derived from the top ranked probes for a set of correlated genes predictive of 
metastatic recurrence latencies, were included in the models. Hazard ratios for these PCs represent the change in hazards per standard deviation 
increase in the variable. A hazard ratio greater than 0 indicates that increasing levels of genes positively correlated with the PC variable are 
associated with an increased risk of metastasis.
2. Hazard ratios for tumor size represent differences in tumor sizes greater than 2 cm versus tumors less than 2 cm.
3. Hazard ratios for grades are relative to grade 1 tumors. Grade variables were not included in the analysis of ER negative tumors due to the low 
numbers of tumors representing the various grades.
4. Hazard ratios are for grade 2 versus other grades.BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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adjustment for the cell-cycle PC variable (Table 2). The
exception was the Wang ER negative predictor, which
remained predictive in the data set from which it was
derived. In contrast to the first PC, all gene lists remained
predictive when adjusted for either the second or third PC
variables (Table 2 and data not shown). Similar results
were obtained when the various PC variables were used to
adjust two additional data sets [see Additional file 2].
We also examined the effect of adjusting for the PC varia-
bles on the 21-gene recurrence score predictor which func-
tions as a clinically approved diagnostic tool for ER
positive tumors [8]. In the NKI2 data set, the predictor
robustly discriminated between high and low risk patients
prior to adjustment (Figures 4A and 4B). However, after
adjusting for the cell-cycle PC, the area-under-the-curve
for the ROC plot decreased from 0.75 to 0.53 and the pre-
dictor was no longer capable of identifying appropriate
high and low risk groups (Figures 4A and 4C). Similar
results were obtained in the KJX64/KJ125 dataset, though
the performance of the predictor was impacted to a lesser
extent by adjustment (Figure 4D). Hazard ratios before
and after adjustment were 6.9 (p = 0.002) and 2.2 (p =
0.18), respectively (90% sensitivity threshold). The recur-
rence score was not predictive in the Wang data set (HR =
2.4, p = 0.18), precluding an assessment of adjusting for
the impact of the cell cycle PC on its function.
Collectively, these analyses revealed that prognostic gene
lists rely on genes whose expression correlates with cell
cycle genes to assign tumors to high and low risk groups
across data sets. Further supporting this conclusion, we
found that when data were adjusted for individual genes,
rather than a PC variable representing a cluster of genes,
the impact of such adjustment on the performance of the
predictor was directly related to the magnitude of that
gene's correlation with the cell cycle PC [see Additional
file 3].
Discussion
Herein, we described an approach to determine biological
commonalities among non-overlapping gene-based clas-
sifiers that are predictive of breast cancer metastases.
Although it has previously been suggested that cellular
proliferation may be an underlying component of these
classifiers, no studies have directly shown that this is,
indeed, the case. To determine if there was a fundamental
biological process that was consistently being interrogated
by these prognostic lists, we developed a method to iden-
tify clusters of correlated genes that are associated with the
risk of developing metastases in breast cancer. The advan-
tage of this method is that it identifies large groups of cor-
related genes whose expression pattern is determined by
common processes associated with an outcome. We sug-
gest that such an approach is necessary when devising
Genes correlated with the cell cycle principal component are  overrepresented on published gene lists Figure 3
Genes correlated with the cell cycle principal compo-
nent are overrepresented on published gene lists. A/
B/C. Each bar graph shows the percentage of the genes 
within selected published prognostic gene lists that have 
Pearson's correlation coefficients greater than 0.4 or less 
than -0.4 to either the first (black bars) or second (grey bars) 
PC variables from each data set evaluated. The bars identified 
as "All probes" represent the percentage of all probes in the 
(A) NKI2 (n = 24,495), (B) KJX64/KJ125 (n = 22,285) and (C) 
Wang (n = 22,286) gene expression data sets that have cor-
relations within the indicated ranges.BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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classifiers because all members of a correlated network
function as a group to relay information regarding a com-
mon pathophysiological state [24]. More importantly,
any one gene from a correlated cluster can act as a sentinel
or reporter for all other genes within that same cluster. As
a result, numerous prognostic lists can be generated which
measure the same biological process but have little to no
overlap in gene content. In addition, analytic approaches
which examine individual probes are apt to identify only
those correlated probes that are strongly associated with
outcome, but not those probes with weaker correlations
since they will only be modestly predictive [25].
Using an iterative-subtractive approach, we consistently
show that the most predictive gene cluster in five inde-
pendent, publicly available breast cancer data sets is rep-
resented by genes that either directly participate in the cell
cycle or whose expression is dictated by cell cycle progres-
sion. Visualization of this cluster in the NKI2 gene expres-
sion data set was particularly striking as it revealed that the
prognostic capacity of virtually every gene was directly
related to that gene's correlation with cell cycle genes (Fig-
ure 2A). Indeed, when data were adjusted to selectively
eliminate the correlations among the genes in this cluster,
very few genes remained predictive of outcome. The
highly correlated nature of all of the predictive genes in
this data set explains why a comparison of the perform-
ance of five prognostic gene lists showed that 4 of 5 per-
formed comparably even though these lists had very little
overlap in their constituent genes [14]. It also reveals why
using only the cell cycle correlated genes from a predictive
gene list is sufficient to recapitulate the performance of the
entire list [15,17,26] – because the other predictive genes
in these lists function as weak proxies of the cell cycle
genes.
A number of studies have identified cell cycle genes as
being predictive of poor outcome within and across can-
cer types [23,27,28]. Cell cycle genes have also been
shown to represent the molecular basis of tumor grade in
breast cancer, a strong predictor of metastasis
[15,16,29,30]. While cell cycle regulators may play a caus-
ative role in tumor development [31], their upregulation
also likely represents an important unifying pathway for a
number of tumor initiating events. As a result, the funda-
mental commonality among all breast cancer subtypes
that predicts outcome is an increase in proliferation. This
outcome further supports the notion that breast cancer is
Table 2: Prognostic gene lists rely on genes correlated with the first (cell cycle) principal component variable1.
Intercept adjusted PC1 adjusted PC2 adjusted
Data set Gene list Good/Poor2 HR (p-value) Good/Poor2 HR (p-value) Good/Poor2 HR (p-value)
NKI2
70 Gene 91/174 5.8 (< 0.0001) 30/235 1.2 (0.67) 90/175 5.7 (< 0.0001)
Wang 76-gene (ER+) 85/60 4.5 (< 0.0001) 44/101 0.9 (0.84) 89/56 2.7 (0.005)
Wang 76-gene (ER-) 6/29 0.9 (0.88) 5/30 1.2 (0.78) 8/27 0.5 (0.25)
Wound Signature 74/221 4.1 (0.0002) 27/268 1 (0.93) 73/22 3.9 (0.0002)
Sotiriou Grade 92/203 4.7 (< 0.0001) 25/270 0.8 (0.8) 91/204 4.7 (< 0.0001)
Naderi 131/104 2.5 (0.0006) 123/112 0.4 (0.003)2 128/107 2.4 (0.0014)
KJX64/KJ125
70 Gene 38/111 2.8 (0.03) 15/134 0.7 (0.4) 39/110 2.9 (0.03)
Wang 76-gene (ER+) 53/36 1.6 (0.32) 35/54 1.2 (0.7) 61/28 1.8 (0.24)
Wang 76-gene (ER-)4 14/5 n/a 16/3 n/a 12/7 n/a
Sotiriou Grade 46/143 2.9 (0.03) 35/154 1.7 (0.24) 46/143 2.7 (0.03)
Naderi 71/56 3.9 (0.004) 69/58 1.6 (0.24) 72/55 3.9 (0.004)
Wang
70 Gene 49/197 2.6 (0.005) 22/224 0.9 (0.41) 44/202 2.3 (0.015)
Wang 76-gene (ER+) 45/84 6.3 (0.0005) 30/99 2 (0.11) 49/80 5.6 (0.0003)
Wang 76-gene (ER-) 26/16 11.7 (0.0001) 29/13 8.2 (0.0001) 15/27 4.9 (0.03)
Sotiriou Grade 57/229 2.5 (0.007) 21/265 0.7 (0.25) 49/237 2 (< 0.0001)
Naderi 106/110 2.4 (0.0008) 105/111 0.9 (0.66) 105/111 3.1 (< 0.0001)
1. Hazard ratios (HR) represent the change in risk for tumors classified as having a poor prognosis versus tumors classified as having a good 
prognosis using a univariate proportional hazards analysis. Gene expression data were independently adjusted using simple linear regression analysis 
for either an intercept only, the principal component representing the first correlated gene cluster identified (PC1) or the second correlated gene 
cluster identified (PC2) in each data set. Univariate HRs that are significantly (p < 0.05) greater than 1 are shown in bold.
2. Values in the Good/Poor column indicate the number of tumors assigned to the good and poor prognosis groups, respectively. The total number 
of tumors per gene list will vary depending upon the number of tumors used in training sets.
3. The fact that this HR is significantly less than 1 indicates that the classifier did not appropriately classify tumors into appropriate good and poor 
prognosis groups.
4. There were too few events among good and poor prognosis groups to perform statistical analyses in the KJX64/KJ125 data set.BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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an amalgam of very different subtypes of disease, with
each subtype having a distinct group of prognostic genes.
When all of these classes of tumors are combined, the
major common theme is cell cycle progression. This con-
cept is further illustrated by the inherent lack of known
mammary oncogenes, such as HER2/ErbB2 [32], in any of
the predictive clusters we identified. A similar observation
has been made in other studies which have used statistical
methods to define prognostic gene sets [6,7,11]. While
expression of cell cycle regulators is upregulated in HER2
tumors as well as ER negative tumors [19,33], HER2 and
ER-α were either uncorrelated or modestly linearly corre-
lated with the cell cycle clusters. The low correlations are
likely due to the fact that these types of tumors represent
a relatively small proportion of tumors in these data sets
and that expression levels of these genes are uncorrelated
with those for the cell cycle genes in the majority of tumor
types. Thus, it is not surprising that these factors would
not be the primary indicators of outcome, either by the
method described herein or with other classifiers, when
examining the entire set of tumors. In contrast, many of
the genes negatively correlated with the cell cycle PC vari-
able were genes that have previously been shown to define
the good prognosis class of Luminal A tumors (e.g.
SCUBE2, XBP1, FoxA1 etc.) [3,20] (data not shown). The
negative correlations may arise either because these genes
inhibit proliferation [34] or because they define a class of
tumors with intrinsically low rates of proliferation. In
either case, from the perspective of predicting metastasis
The Recurrence Score prognosticator fails to perform appropriately after adjustment for the cell cycle principal component  variable Figure 4
The Recurrence Score prognosticator fails to perform appropriately after adjustment for the cell cycle princi-
pal component variable. A. A ROC curve summarizing the performance of the 21-gene recurrence classifier in ER positive 
tumors in the NKI2 data set (n = 224 subjects) adjusted for either an intercept only (black line) or the cell cycle PC variable 
(grey line). The area under the curve (AUC) for each analysis is shown on the graph. The dotted line represents a ROC curve 
with an AUC of 0.5 (indicative of a low accuracy test). B/C. Kaplan-Meier plots for the recurrence score in the NKI2 data set 
for data adjusted for (B) intercept-only or (C) the cell cycle PC variable. Hazard ratios (HR) and p-values are from univariate 
proportional hazards analyses and represent the difference in hazards for poor versus good prognosis tumors. D. ROC curve 
for ER positive tumors in the KJX64/KJ125 data set (n = 147 subjects) adjusted for either an intercept only (black line) or the 
cell cycle PC variable (grey line).BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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latencies, they all function to various degrees as proxies
for the cell cycle.
Conclusion
Prognostic tools for breast cancer that utilize gene-based
classifiers are currently being tested or used in clinical set-
tings [35]. As more of these prognostic tools become com-
mercially available, it will be imperative to have a
thorough understanding of how they may differ in order
to facilitate selection of the most appropriate test. Our
studies suggest that these tools, despite having little over-
lap in gene content, rely heavily on a single metric to iden-
tify high and low risk tumors. The common biological
process that is being measured is the upregulation of
genes associated with cell proliferation. Consistent with
this conclusion is the fact that the greatest overlap in
established classifiers is typically genes encoding cell cycle
regulators [7]. Furthermore, the cell cycle cluster of genes
(PC1 for each data set) was as effective as all of the other
established classifiers we examined when used to evaluate
data sets other than those from which they were derived
(Table 2) [see Additional file 2]. Most importantly, adjust-
ment of the data sets for this cluster resulted in a loss of
the predictive capacity for these classifiers, indicating that
they require measuring fluctuations in the cell cycle corre-
lated genes to effectively separate tumors into high and
low risk groups. These findings suggest that validation of
novel classifying gene lists should involve a comparison
with a prognosticator comprised of a small number of cell
cycle associated genes, as such a classifier may be able to
capture the same amount of critical prognostic informa-
tion with a smaller number of genes This study also
underscores the fact that many genes are correlated with
the cell cycle genes even though they may not be directly
associated with this process. Thus, simply removing
known cell cycle regulatory genes from a gene expression
data set or prognostic classifier is insufficient to adjust for
the contribution of cellular proliferation in a prognostic
gene list.
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Additional File 1
Example of the scoring procedure for two genes in a simulated gene expres-
sion data set. For each gene within the data set, a Pearson's correlation 
coefficient was computed for that gene vs. every other gene in the data set. 
In addition, a p-value for the univariate hazard ratio was also calculated 
for each gene. A scatter plot was constructed to compare the log of the p-
value for the univariate hazard ratio for all genes versus their correlation 
to the individual gene being scored. Each graph shown includes only those 
genes that are positively correlated with the gene being scored. Each point 
on the graph represents the data for one of these positively correlated 
genes. The values for the covariance (cov) and the Pearson's correlation 
coefficient (corr), both computed using the data shown on the graphs, as 
well as the composite score are shown on the figures. The composite score 
was computed as follows:
Score = AbsoluteValue(Cov) * Corr
This approach was repeated for every gene in the data set. A. Scatterplot 
for a gene that is highly correlated with a set of genes whose expression is 
also associated with outcome. This is the top-scoring gene in the simulated 
data set. Note that many genes with a high correlation with the gene of 
interest also have a small significant hazards ratio p-value. B. Scatterplot 
for a gene receiving a low score that is not correlated with genes associated 
with the outcome.









The impact of adjusting for a specific gene is determined by that gene's cor-
relation to the cell cycle principal component variable. Scatter plot show-
ing the impact of individually adjusting for each of the 24,495 probes in 
the NKI2 data set on the performance of the "70-gene" predictor. The 
graph is a plot of the negative log of the p-value for a univariate HR com-
paring good versus poor prognosis tumors after globally adjusting the gene 
expression data for an individual probe versus the correlation of that probe 
to the cell cycle PC variable. Each point on the graph shows the impact of 
adjusting for a single probe on the performance of the classifier. The p-
value shown on the y-axis is for the univariate HR computed after the data 
were globally adjusted for a given gene. The graph demonstrates that 
adjustment for genes that are highly correlated with the cell cycle PC 
greatly attenuate the prognostic power of this predictor. In contrast, 
adjusting for genes that are not correlated with the PC, including those 
that comprise the predictor, has little impact on its performance.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8794-1-11-S3.tiff]BMC Medical Genomics 2008, 1:11 http://www.biomedcentral.com/1755-8794/1/11
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